Kintor Pharmaceutical Ltd (09939.HK)価格

Kintor Pharmaceutical Ltd. is a clinical-stage novel drug developer in China, which engages in the proprietary research and development of innovative medicine products for cancers and other Androgen receptor-related diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 136 full-time employees. The company went IPO on 2020-05-22. The firm's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The firm has two core drugs in the dermatology field, KX-826 and GT20029. The firm's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.